Creatine and Depression: What the Evidence Really Shows

Creatine has moved well beyond the weight room. Once discussed primarily in relation to strength, power and muscle growth, the supplement is now promoted for healthy aging, cognitive performance, brain health and even the treatment of depression. As the claims expand, your clients may look to you for help separating credible findings from social media enthusiasm.

A recent systematic review offers a timely reason to have that conversation. Researchers found some encouraging results when creatine was added to established treatments for depression, but the overall evidence was mixed. The number of clinical trials was small, their methods varied and most participants were women. The findings raise worthwhile research questions, but they do not establish creatine as a treatment for depression.

As a health and exercise professional, it’s important to understand what you can and can’t do with this type of research. When it comes to educating your clients, you can help them understand the general state of the science, correct exaggerated claims and direct them toward trustworthy resources. What you should avoid, however, is recommending a supplement, determining an appropriate dosage or using it to address a mental health condition that requires a qualified healthcare professional.

Why Researchers Are Looking at the Brain

Creatine helps cells manage rapidly changing energy demands. Through the creatine-phosphocreatine system, it supports the regeneration of adenosine triphosphate, or ATP, which cells use for energy, and contributes to short-duration, high-intensity muscular efforts. The brain is also highly energy dependent, which has led researchers to investigate whether creatine availability could influence brain function.

Some studies have identified differences in brain creatine metabolism among people with mood disorders and other neuropsychiatric conditions. Researchers have also proposed that creatine could affect pathways involving dopamine and serotonin. These ideas provide a biological rationale for further investigation, but they do not demonstrate that low creatine causes depression or that supplementation will relieve it. The association between brain creatine metabolism and mood disorders remains inconsistent, and depression has many interacting biological, psychological and social contributing factors.

What the Review Examined

For the full systematic review of randomized controlled trials, researchers searched four major databases through Sept. 30, 2025. They found six published articles reporting results from five randomized controlled trials. Together, the trials included 238 participants at baseline, with 126 assigned to creatine and 112 assigned to a placebo. Participants were 36 years old on average and only 26% were men. Two trials enrolled women exclusively.

Four trials involved people diagnosed with major depressive disorder, and one involved people with bipolar disorder who were experiencing a depressive episode. No eligible randomized controlled trials examined creatine supplementation for other mental health disorders.

Creatine monohydrate was studied in amounts ranging from 2 to 10 grams per day over four to eight weeks. Importantly, researchers evaluated creatine as an addition to medication or psychotherapy rather than as a replacement for standard treatment. Because the trials differed substantially in their participants, treatment approaches, dosages and outcome measures, the researchers summarized them individually instead of combining the results in a meta-analysis.

The Most Promising Findings

The most promising findings came from two trials involving women with major depressive disorder.

In one eight-week trial, participants received either 5 grams of creatine monohydrate per day or a placebo. All participants received the antidepressant escitalopram. The creatine group experienced greater reductions in depressive symptoms and higher remission rates. On a standard measure of depression symptoms, the creatine group improved substantially more than the placebo group—a difference researchers considered large.

Another trial paired creatine with cognitive behavioral therapy. Participants receiving creatine and therapy reported greater symptom improvement than those receiving therapy and a placebo. This result is notable because it suggests that the possible benefit may not be limited to medication augmentation. It remains one small trial, however, and requires replication in larger and more representative samples.

Where Creatine Did Not Help

Three trials found no meaningful advantage over a placebo.

One study tested 5- and 10-gram daily amounts in adults whose depression had not responded adequately to medication. Neither amount produced a significant treatment effect after four weeks. An eight-week study of adolescent girls also found no significant differences among groups receiving 2, 4 or 10 grams per day or a placebo.

The bipolar disorder trial found no improvement in depressive symptoms when 6 grams of creatine per day was added to medication. Two of the 17 participants receiving creatine developed hypomania or mania. The small number of participants prevents firm conclusions about the level of risk, but the finding is clinically important and reinforces why clients should not use creatine to self-treat a mental health condition.

Study coauthor Bassam Jeryous Fares believes the findings are interesting, “but it is not a verdict.” While two trials pointed toward a possible benefit, three did not, which is enough to support additional research but not a change in clinical practice.

Why the Evidence Remains Uncertain

The review’s limitations go well beyond the conflicting results. Five trials and 238 baseline participants represent a very small evidence base. The studies lasted no longer than eight weeks, used multiple dosages and included different age groups, diagnoses and established treatments.

The limited representation of men also makes it difficult to apply the findings broadly. Researchers do not yet know whether sex influences the relationship between creatine and depressive symptoms. The strongest positive result came from a study of women, but that pattern could reflect a true difference, the specific characteristics of the participants or chance.

Two trials were rated as having a low risk of bias, while three raised some concerns related to randomization or missing data. Most adverse effects were limited to mild gastrointestinal symptoms, but good tolerability in a small, short-term trial does not establish effectiveness or guarantee safety for every individual. The findings also can’t tell us whether creatine works as a stand-alone intervention. Positive outcomes occurred when it was added to antidepressant medication or cognitive behavioral therapy, and nothing in the review supports replacing psychotherapy, medication or medical care with a supplement.

Practical Application: Educate Without Prescribing

Clients do not need you to endorse or dismiss every health claim they encounter. They benefit when you help them interpret the evidence in proportion to its strength.

When a client asks whether creatine can treat depression, explain that researchers have identified a possible benefit in two small trials, while three other trials found no meaningful improvement. Emphasize that creatine was studied as an addition to medication or psychotherapy and has not been shown to replace either one. You can also explain that researchers identified a potential safety concern in the bipolar disorder trial, where two participants receiving creatine developed hypomania or mania, and that long-term, broadly representative research is still lacking.

A response might sound like this: “Creatine has good research support for some strength and exercise-performance outcomes, but the evidence related to depression is limited and mixed. Because using a supplement to address a mental health condition falls outside my scope of practice, this would be a good question to discuss with your physician or registered dietitian nutritionist.”

The ACE Position Statement on Nutritional Supplements states that recommending, prescribing, selling or supplying nutritional supplements falls outside an exercise professional’s defined scope of practice. ACE advises professionals to work with a registered dietitian nutritionist or physician when a client wants individualized supplement guidance.

That boundary still leaves room for meaningful education. You can share peer-reviewed resources, explain the difference between a randomized controlled trial and a social media testimonial, and clarify that evidence for one outcome does not automatically transfer to another. Creatine’s ability to support strength gains, for example, does not prove that it improves depression, memory, sleep, longevity or every other outcome attached to it online. Evaluating general research and directing clients to credible educational resources can be appropriate, provided that the conversation does not become an individualized recommendation.

You can also encourage clients to tell their treating healthcare professionals about supplements they already use or are considering. This is particularly important when the client has a diagnosed mental health condition, takes medication, is pregnant, has a medical condition or is considering a supplement in place of prescribed care.

Your direct contribution remains exercise and behavior-change support within your qualifications. You can design an appropriate program, help the client identify manageable ways to be active, collaborate with members of the health care team when authorized and reinforce the client’s treatment plan without interpreting symptoms or directing mental health care.

Keep the Claim in Proportion

Creatine deserves attention because it is extensively studied for certain exercise outcomes and may have applications that extend beyond skeletal muscle. Depression research has reached a much earlier stage. A small number of inconsistent trials suggests that this is a question worth pursuing, but clients shouldn’t take these current findings as something they should act on without clinical guidance.

By communicating that distinction clearly, you can reduce hype without dismissing promising science—and help clients take their questions to the professionals qualified to answer them.